These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28867699)

  • 1. Frequency of Acute Kidney Injury Caused by Tazobactam/Piperacillin in Patients with Pneumonia and Chronic Kidney Disease: A Retrospective Observational Study.
    Morimoto T; Nagashima H; Morimoto Y; Tokuyama S
    Yakugaku Zasshi; 2017; 137(9):1129-1136. PubMed ID: 28867699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia].
    Oizumi K; Ohno T; Kawahara M; Kawaguchi S; Saisho M; Mitutake Y; Saito A; Tomizawa M; Koike T; Takebe K
    Jpn J Antibiot; 1995 Apr; 48(4):449-81. PubMed ID: 7783313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A comparative study of tazobactam/piperacillin and piperacillin in chronic respiratory tract infections].
    Oizumi K; Kawahara M; Kawaguchi S; Sigematsu H; Tanaka F; Sano N; Saito A; Hiraga Y; Ohmichi M; Inoue H
    Jpn J Antibiot; 1995 Apr; 48(4):482-513. PubMed ID: 7783314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of acute kidney injury after teicoplanin- or vancomycin- and piperacillin/tazobactam combination therapy: A comparative study using propensity score matching analysis.
    Sazanami K; Inose R; Yagi T; Dote S; Horiuchi N; Kobayashi Y; Muraki Y
    J Infect Chemother; 2021 Dec; 27(12):1723-1728. PubMed ID: 34446352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Investigation of the Efficacy of an Administration Plan for Tazobactam/Piperacillin (TAZ/PIPC) and the Incidence of Kidney and Hepatic Disorders].
    Senba M; Isami K; Yamashita K; Tsumagari K; Yamashina T; Sasaki E; Tsuruta M; Miyoshi T; Kawamata Y; Kozono A
    Yakugaku Zasshi; 2017; 137(10):1277-1284. PubMed ID: 28966268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrotoxicity induced by piperacillin–tazobactam in late elderly Japanese patients with nursing and healthcare associated pneumonia.
    Karino F; Nishimura N; Ishihara N; Moriyama H; Miura K; Hamaguchi S; Sutani A; Kuraki T; Ikawa K; Morikawa N
    Biol Pharm Bull; 2014; 37(12):1971-6. PubMed ID: 25590089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Retrospective Analysis of Factors Decreasing the Efficacy of Tazobactam/Piperacillin for Pneumonia in Elderly Patients].
    So M; Oda K; Ota K; Sakamoto N; Suzuki T
    Yakugaku Zasshi; 2018; 138(4):581-588. PubMed ID: 29608008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan.
    Yamamoto Y; Izumikawa K; Morinaga Y; Nakamura S; Kurihara S; Imamura Y; Miyazaki T; Tsukamoto M; Kakeya H; Yanagihara K; Yasuoka A; Kohno S
    J Infect Chemother; 2013 Apr; 19(2):291-8. PubMed ID: 23345050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.
    Kobayashi I; Ikawa K; Nakamura K; Nishikawa G; Kajikawa K; Yoshizawa T; Watanabe M; Kato Y; Zennami K; Kanao K; Tobiume M; Yamada Y; Mitsui K; Narushima M; Morikawa N; Sumitomo M
    J Infect Chemother; 2015 Aug; 21(8):575-80. PubMed ID: 26050020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetic, bacteriological and clinical evaluation of tazobactam/piperacillin in pediatrics].
    Iwai N; Nakamura H; Miyazu M
    Jpn J Antibiot; 1998 May; 51(5):346-61. PubMed ID: 9693967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa.
    Yamagishi Y; Terada M; Ohki E; Miura Y; Umemura T; Mikamo H
    J Infect Chemother; 2012 Feb; 18(1):127-9. PubMed ID: 21814800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients.
    Kobayashi R; Hori D; Sano H; Suzuki D; Kishimoto K; Kobayashi K
    J Microbiol Immunol Infect; 2018 Aug; 51(4):473-477. PubMed ID: 28690028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
    Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA
    Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
    Burgess LD; Drew RH
    Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
    Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
    Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients.
    Hundeshagen G; Herndon DN; Capek KD; Branski LK; Voigt CD; Killion EA; Cambiaso-Daniel J; Sljivich M; De Crescenzo A; Mlcak RP; Kinsky MP; Finnerty CC; Norbury WB
    Crit Care; 2017 Dec; 21(1):318. PubMed ID: 29262848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Factors for Teicoplanin-Associated Acute Kidney Injury in Patients with Hematological Malignancies: Focusing on Concomitant Use of Tazobactam/Piperacillin.
    Morinaga Y; Tanaka R; Tatsuta R; Takano K; Hashimoto T; Ogata M; Hiramatsu K; Itoh H
    Biol Pharm Bull; 2024; 47(5):988-996. PubMed ID: 38763761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetic and clinical evaluation of tazobactam/piperacillin in the pediatric field].
    Toyonaga Y; Ishihara T; Tezuka T; Nakamura H
    Jpn J Antibiot; 1998 May; 51(5):325-45. PubMed ID: 9693966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effectiveness and safety of tazobactam/piperacillin 4.5 g for the prevention of febrile infectious complication after prostate biopsy.
    Yasuda M; Nakane K; Yamada Y; Matsumoto M; Sho T; Matsumoto M; Kobayashi K; Shigemura K; Nakano Y; Tanaka K; Hamasuna R; Ishihara S; Arakawa S; Yamamoto S; Matsubara A; Fujisawa M; Deguchi T; Matsumoto T
    J Infect Chemother; 2014 Oct; 20(10):631-4. PubMed ID: 25043444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.
    Karino S; Kaye KS; Navalkele B; Nishan B; Salim M; Solanki S; Pervaiz A; Tashtoush N; Shaikh H; Koppula S; Martin ET; Mynatt RP; Murray KP; Rybak MJ; Pogue JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3743-50. PubMed ID: 27067325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.